Nonetheless, our results that the inflammatory response in the presence of the α-COP variants can be effectively suppressed by STING palmitoylation inhibitors may provide a treatment approach for COPA syndrome patients. This evidence concerns the gene STING1 and autoimmune interstitial lung disease-arthritis syndrome.